[go: up one dir, main page]

MX2009008617A - Uso de antagonistas de interleucina-23 para el tratamiento de infeccion. - Google Patents

Uso de antagonistas de interleucina-23 para el tratamiento de infeccion.

Info

Publication number
MX2009008617A
MX2009008617A MX2009008617A MX2009008617A MX2009008617A MX 2009008617 A MX2009008617 A MX 2009008617A MX 2009008617 A MX2009008617 A MX 2009008617A MX 2009008617 A MX2009008617 A MX 2009008617A MX 2009008617 A MX2009008617 A MX 2009008617A
Authority
MX
Mexico
Prior art keywords
antagonists
treatment
infection
infections
viral
Prior art date
Application number
MX2009008617A
Other languages
English (en)
Inventor
Robert A Kastelein
Manfred Kopf
Luigina Romani
Alissa A Chackerian
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2009008617A publication Critical patent/MX2009008617A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proveen métodos y composiciones que comprenden antagonistas de IL-23 para el tratamiento de infecciones, tales como infecciones bacterianas, virales y fúngicas crónicas.
MX2009008617A 2007-02-12 2008-02-08 Uso de antagonistas de interleucina-23 para el tratamiento de infeccion. MX2009008617A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88947507P 2007-02-12 2007-02-12
PCT/US2008/001717 WO2008153610A2 (en) 2007-02-12 2008-02-08 Use of il-23 antagonists for treatment of infection

Publications (1)

Publication Number Publication Date
MX2009008617A true MX2009008617A (es) 2009-10-14

Family

ID=40130357

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008617A MX2009008617A (es) 2007-02-12 2008-02-08 Uso de antagonistas de interleucina-23 para el tratamiento de infeccion.

Country Status (13)

Country Link
US (2) US8586035B2 (es)
EP (1) EP2064246B1 (es)
JP (2) JP5320301B2 (es)
CN (1) CN101668775B (es)
AU (1) AU2008262544B2 (es)
BR (1) BRPI0807487A8 (es)
CA (1) CA2677835A1 (es)
CL (1) CL2008000418A1 (es)
MX (1) MX2009008617A (es)
NZ (2) NZ578955A (es)
TW (1) TWI426918B (es)
WO (1) WO2008153610A2 (es)
ZA (1) ZA200906126B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI426918B (zh) * 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
EP2254998B1 (en) * 2008-02-28 2015-12-23 Argos Therapeutics, Inc. Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection
WO2010027767A1 (en) * 2008-08-27 2010-03-11 Schering Corporation Engineered anti-il-23r antibodies
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
MX362039B (es) 2010-11-04 2019-01-07 Boehringer Ingelheim Int Anticuerpos anti-il-23.
WO2012093127A2 (en) * 2011-01-04 2012-07-12 Universität Zürich Modulators of il-12 and/or il-23 for the prevention or treatment of alzheimer's disease
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CA2811250C (en) 2011-10-21 2015-08-11 Abbvie Inc. Methods for treating hcv
SE1450019A1 (sv) 2011-10-21 2014-01-10 Abbvie Inc Förfaranden för att behandla HCV innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
KR102124758B1 (ko) 2012-05-03 2020-06-19 베링거 인겔하임 인터내셔날 게엠베하 항-ｉｌ-23ｐ19 항체
WO2014004436A2 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
WO2015157561A1 (en) * 2014-04-09 2015-10-15 La Jolla Institute For Allergy And Immunology Specific and unique t cell responses and molecular signatures for treatment and diagnosis of mycobacterium tuberculosis
JP2017524359A (ja) 2014-07-24 2017-08-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２３ａ関連疾患の処置に有用なバイオマーカー
MX388301B (es) 2014-09-03 2025-03-19 Boehringer Ingelheim Int Il-23a y tnf-alfa orientados y compuesto y sus usos.
KR20240158362A (ko) 2015-02-04 2024-11-04 베링거 인겔하임 인터내셔날 게엠베하 염증성 질환의 치료 방법
CN105420238A (zh) * 2015-09-08 2016-03-23 中国农业科学院兰州兽医研究所 靶向抑制小鼠白细胞介素17A基因的序列siRNA-136
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALKYNOUS THERAPEUTIC NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND RELATED APPLICATIONS
EP3534910A4 (en) * 2016-10-04 2020-11-25 Pop Test Oncology LLC THERAPEUTIC METHODS AND AGENTS
WO2018204374A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3634405A4 (en) * 2017-05-12 2021-06-09 The Regents of The University of California METHODS OF DETECTING DYSBIOSIS AND TREATING PATIENTS WITH DYSBIOSIS
CN108743603B (zh) * 2018-06-22 2020-06-30 山东省千佛山医院 利巴韦林单用或联合氟康唑的抗真菌产品及其应用
BR112021008873A8 (pt) 2018-11-07 2023-04-11 Merck Sharp & Dohme Formulação
US20220000944A1 (en) * 2018-11-09 2022-01-06 The Ritsumeikan Trust Agent for controlling sebaceous glands
KR20220143005A (ko) * 2019-12-20 2022-10-24 노바록 바이오테라퓨틱스 리미티드 항-인터루킨-23 p19 항체 및 이의 사용 방법
CN112500490B (zh) * 2020-10-14 2022-05-03 华南农业大学 一种抗左旋氧氟沙星抗体的F(ab)2片段及其制备方法和应用
CN118873519A (zh) * 2024-08-22 2024-11-01 首都医科大学附属北京胸科医院 萘替芬在抗偶发分枝杆菌感染中的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144346A (en) 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
US4218458A (en) 1978-06-23 1980-08-19 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
DE3262386D1 (en) 1981-06-06 1985-03-28 Pfizer Ltd Antifungal agents, processes for their preparation, and pharmaceutical compositions containing them
CA2265824C (en) 1996-09-12 2004-11-09 Merck & Co., Inc. Antifungal combination therapy
PE20000183A1 (es) 1997-07-25 2000-03-11 Schering Corp Citoquinas de mamiferos y reactivos relacionados
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
MXPA01012331A (es) 1999-06-01 2002-07-30 Schering Corp Proteinas receptoras de mamiferos, reactivos y metodos relacionados.
IL148300A0 (en) 1999-09-09 2002-09-12 Schering Corp Mammalian cytokines; related reagents and methods
PL209128B1 (pl) 2000-05-10 2011-07-29 Schering Corp Białko receptora spokrewnionego z receptorami cytokin oraz związane z nim produkty, sposoby i zastosowania
AUPR381601A0 (en) * 2001-03-19 2001-04-12 Monash University Method of treating respiratory conditions
JP2004536800A (ja) * 2001-05-09 2004-12-09 アルカベロ アクチェセルスカプ Ｔｈ１／ｔｈ２比を変調することによりｔｈ１及びｔｈ２細胞関連疾患を予防又は治療するための医薬組成物
CA2501786C (en) 2002-10-30 2015-02-17 Genentech, Inc. Inhibition of il-17 production
TWI357336B (en) * 2003-03-10 2012-02-01 Schering Corp Uses of il-23 agonists and antagonists; related re
CA2522007A1 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Methods of preventing or treating respiratory conditions
CN101052726A (zh) 2003-05-09 2007-10-10 森托科尔公司 IL－23p40特异性免疫球蛋白衍生蛋白、组合物、方法和用途
ES2751414T5 (es) 2003-07-08 2024-04-23 Novartis Pharma Ag Anticuerpos antagonistas a polipéptidos heterólogos IL-17 A/F
GB0329146D0 (en) 2003-12-16 2004-01-21 Glaxosmithkline Biolog Sa Vaccine
WO2005079837A1 (en) * 2004-02-17 2005-09-01 Schering Corporation Methods of modulating il-23 activity; related reagents
US20060193821A1 (en) 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
GB0507561D0 (en) 2005-04-14 2005-05-18 Trinity College Dublin Modulation of an immune response by filamentous haemagglutinin
EP1896073B1 (en) * 2005-06-30 2013-03-06 Janssen Biotech, Inc. Anti-il-23 antibodies, compositions, methods and uses
BRPI0615018A2 (pt) 2005-08-25 2011-04-26 Lilly Co Eli anticorpos anti-il-23, ou porção de ligação de antìgeno do mesmo, composição contendo o mesmo e referido uso
EP2354160A1 (en) 2005-08-31 2011-08-10 Schering Corporation Engineered anti-IL-23-antibodies
PT2548577T (pt) 2005-12-29 2017-05-29 Janssen Biotech Inc Anticorpos humanos anti-il-23, composições, métodos e usos
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
MX2009001620A (es) 2006-08-11 2009-02-23 Schering Corp Anticuerpos para il-17a.
TWI426918B (zh) * 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
CA2678863A1 (en) 2007-02-23 2008-08-28 Schering Corporation Engineered anti-il-23p19 antibodies
DK2426144T3 (en) 2007-02-23 2019-01-07 Merck Sharp & Dohme Manipulated Anti-IL-23P19 Antibodies
NZ579251A (en) 2007-02-28 2012-06-29 Schering Corp Engineered anti-il-23r antibodies
WO2010027767A1 (en) 2008-08-27 2010-03-11 Schering Corporation Engineered anti-il-23r antibodies

Also Published As

Publication number Publication date
WO2008153610A3 (en) 2009-03-19
CL2008000418A1 (es) 2008-11-14
TW200902062A (en) 2009-01-16
NZ578955A (en) 2012-06-29
AU2008262544A1 (en) 2008-12-18
US20100291084A1 (en) 2010-11-18
US20140147442A1 (en) 2014-05-29
CN101668775A (zh) 2010-03-10
WO2008153610A2 (en) 2008-12-18
EP2064246B1 (en) 2013-05-22
US8586035B2 (en) 2013-11-19
ZA200906126B (en) 2010-06-30
JP2013014624A (ja) 2013-01-24
BRPI0807487A8 (pt) 2016-02-10
JP5320301B2 (ja) 2013-10-23
NZ599827A (en) 2013-11-29
BRPI0807487A2 (pt) 2015-09-01
AU2008262544B2 (en) 2014-01-16
CN101668775B (zh) 2014-05-07
TWI426918B (zh) 2014-02-21
CA2677835A1 (en) 2008-12-18
JP2010518087A (ja) 2010-05-27
EP2064246A2 (en) 2009-06-03

Similar Documents

Publication Publication Date Title
MX2009008617A (es) Uso de antagonistas de interleucina-23 para el tratamiento de infeccion.
WO2008115281A3 (en) Compounds for treating viral infections
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
IL250858A0 (en) Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
MY181898A (en) Heterocyclic compounds and uses thereof
MX2010002318A (es) Derivados azaindol 2,3-sustituidos para tratar infecciones virales.
WO2012076293A9 (de) Zubereitungen enthaltend polysiloxane mit stickstoffhaltigen gruppen
MX2011008920A (es) Composiciones oticas utiles para el tratamiento de infecciones del oido interno y externo en mamiferos.
WO2009105513A8 (en) Novel compounds and methods for therapy
ZA200701629B (en) Gyrase inhibitors and uses thereof
WO2008127364A3 (en) Antiviral compounds and use thereof
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
AU2015352440B2 (en) Compounds
WO2009158374A3 (en) Inhibitors of akt activity
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
MX2016007626A (es) Peptido antimicrobiano y usos del mismo.
GEP201606595B (en) (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) –nifuratel
MX2009009743A (es) Polvos para reconstitucion.
CL2008001322A1 (es) Compuestos derivados de triazolil-aminopirimidina, sustituida con heterociclos; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2011002967A1 (es) Compuestos derivados de 3-oxadiazolil-5-fenil-piperidina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamient y/o profilaxis de trastornos cardiovasculares, tromboembolicos y tumorales.
MX337145B (es) Composiciones farmaceuticas.
WO2011130419A3 (en) Broad spectrum antiviral and antiparasitic agents
WO2011019423A3 (en) Modulation of pilr receptors to treat microbial infections

Legal Events

Date Code Title Description
HH Correction or change in general
HC Change of company name or juridical status

Owner name: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC

FG Grant or registration